Here are some facts for those looking for real answers!
Here are some facts for those looking for real answers! Removed by admin on the pump and dump board!
Among all the inaccurate things that are stated about Cellceutix the top 2 seem to be time line and credibility. Both can be squashed with good DD. Many words have been twisted (some by accident, some by agenda) to try and highlight non issues. As the company moves forward, especially in such a position of success, there will be many that try to mince every word that is written and or said.
Facts -
The company never gave any time line to up-list except one time in an interview saying the plan was for this year (2015) The rumblings that this has lead investors wrong is very inaccurate! As good as Cellceutix has been at keeping investors updated(I for one have appreciated), has also keep the wolves close by the door (the sheep outfits look more and more real I must say!). Giving them the opportunity to smash down every bit of news that is released and turn it in to a non event. So they will keep carrying that torch and may proclaim that partner or up-list is the only way to save the company.The company doesn't require a high SP to conduct and continue through trials this has been discussed ad nausseam! They only thing the attacks on the company have done was drop SP it hasn't slowed anything else down! Well maybe partner discussions, but I don't even think that matters as Cellceutix stands in a position to negotiate anyway.
When your doing your DD find it in print. You will be told things like Phase 2 is meaningless phase 3 is the answer (The same folks say that about everything that has been released) As phase 3 is a given now and just waiting for the "real" time it takes to set up a trial. But if you look at the phase 2 results you will see phase 3 has been very de-risked by the quality of the results. Kevetrin is the same thing phase one took longer than self proclaimed "experts" thought it should. But the quality of the results are outstanding!
Cellceutix isn't a guaranteed success by no means. But if you take a look at where it is, I would much rather be putting my money in a bio with 5 trials, 3 major drugs and phase 2s going on and completed and a phase 3 about to start, over a bio with one drug. Do the math look around compare values of companies.
When you get to money "issue" they have a lot of funding on hand, should they need it. Take a good look at how much the company is burning through! They are using a lot of grants and some trials they are just supplying the drugs.
It is time to take a look at the man behind the mako curtain(it isn't just one) and make a real assessment of the company if you are really considering investing in the company on the long side!
I will only respond to real comments, tomorrow!
Know What you own
Innovation Pharmaceuticals Inc (IPIX) Stock Research Links
Keep in mind that message boards require you to agree to thier manipulation or you are a lying basher! Also remember those that accuse are often riddle with quilt of performing the same which they accuse.
Scroll down for more posts ▼
Top 10 Most Recent News Articles
An Uptick in BTC Staking Yields Seems like Bybit's got a trick up their sleeve with their latest move. They've hiked BTC staking yields from a static 0.8% up to a more attractive 1.2%. Now, if you're parked with Bitcoin in this dicey market, that's a substantial 50% leap upwards. When you think about those dreamy numbers traders like me fantasize about, it’s a juicy...
Continue Reading
Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...
Continue Reading
A Troubling Chapter for Sarepta Therapeutics It's not every day that a company's dirty laundry gets hung out for all to see, especially when we're talking about Sarepta Therapeutics, a player in the rare disease treatment space. But that's exactly where we find ourselves this fine day—a bit like kicking a hornet's nest, if you ask me. Led by the former Louisiana...
Continue Reading
Woodland Direct Takes a Bold Step Westward It's no small feat when a company's growing pains turn into growing gains, yet that's exactly what Woodland Direct has managed to pull off with their latest expansion strategy. The Auburn Hills-based e-commerce juggernaut, synonymous with high-quality fire products, just cut the ribbon on a sparkling new 47,000-square-foot...
Continue Reading
FirstEnergy's Potomac Edison Pushes for Rate Adjustment The walls are closing in on the energy sector, and Potomac Edison is seizing the moment. With their proposed $52.8 million rate adjustment, they're not only aiming to keep the lights on but to power up their entire infrastructure game. It's a gutsy move, particularly in volatile times. The Price Tag: Weighing Costs...
Continue Reading
Here's the move: Primero Games, the U.S.-based gaming maestro, just grabbed a hefty piece of the puzzle with their acquisition of Win Systems' Gaming Division. Not two companies merging into obscurity, but a strategic maneuver aiming to scatter new seeds in Latin America and the Caribbean with over 3,000 gaming positions primed and ready. What's in the Pot? You've got...
Continue Reading
Stepping into the Connectivity Future at IFA 2026 GlocalMe, a name synonymous with global mobile connections, made a splash at the IFA 2026 in Berlin. Equipped with a lineup built for the future, their presentation focused on lifestyle gadgets designed for constant online access. In a world where digital connection feels as vital as air, they've aligned perfectly with the...
Continue Reading
Expansion of Penetron's Engineering Support Eyes are on the Midwest and Central USA as Penetron makes a strategic move to bolster their technical support dream team. They've snagged Sean Allison, a heavyweight with more than three decades' worth of grit and know-how from the construction battlefield. Sean, now stationed in the heart of America's Dairyland—Green Bay,...
Continue Reading
Hyundai's Major Steel Move: A Multibillion-Dollar Stake The steel industry scene in the U.S. just got a lot hotter with Hyundai's announcement of a $5.8 billion Electric Arc Furnace-based integrated steel mill in Louisiana. This game-changing project isn’t just a headline; it’s a concrete step towards beefing up the U.S. manufacturing backbone. Talk about...
Continue Reading
Building Bridges Through Community Investment Well, ain't this something? Columbia, Tennessee, just got a splash of fresh air. We're talking about the new Southern Regional Technology Center nested in Columbia State Community College. Now, the name on everyone's lips? The TriStar Bank Community Room. But it ain't just about a name plastered up on a wall inside a shiny...
Continue Reading
Top 5 Most Recently Viewed Articles
Banco Comercial Português Expands Capital with Tier 2 Notes Banco Comercial Português, S.A. has recently made a significant announcement regarding the issuance of Tier 2 Notes. This move is part of the bank's efforts to strengthen its capital structure and support its growth strategy in the financial sector. Understanding Tier 2 Notes Tier 2 Notes are a type of debt...
Continue Reading
Sony Semiconductor Solutions Introduces Advanced Imaging Technology Sony Semiconductor Solutions Corporation (SSS) is set to revolutionize the world of industrial imaging with the launch of its state-of-the-art IMX925 stacked CMOS image sensor. This innovative sensor features a back-illuminated pixel structure and incorporates a global shutter, marking a significant...
Continue Reading
Center for the Rights of Abused Children Receives Prestigious Award The Center for the Rights of Abused Children has been honored with the Norman Borlaug Humanitarian Award from Vizient. This notable award comes with a monetary gift of $50,000, highlighting the organization’s remarkable dedication to safeguarding vulnerable children. Celebrating Outstanding Leadership...
Continue Reading
Understanding New Dividend Stocks Finding new dividend stocks can be an exciting opportunity for investors, particularly those looking to establish a reliable income stream. Newer dividend issuers are often committed to maintaining and increasing their payouts, indicating strong management and growth prospects. Companies that initiate dividends typically demonstrate...
Continue Reading
Understanding the Skechers and 3G Capital Merger Skechers U.S.A., Inc. (NYSE: SKX) has recently been in the spotlight regarding its acquisition by the global investment firm 3G Capital. This announcement has raised eyebrows among stakeholders and legal experts alike, particularly concerning the fairness of the transaction and potential conflicts of interest. Julie &...
Continue Reading